Yuning Liao

2.1k total citations
58 papers, 1.6k citations indexed

About

Yuning Liao is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yuning Liao has authored 58 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 15 papers in Oncology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yuning Liao's work include Ubiquitin and proteasome pathways (27 papers), Allergic Rhinitis and Sensitization (9 papers) and Histone Deacetylase Inhibitors Research (9 papers). Yuning Liao is often cited by papers focused on Ubiquitin and proteasome pathways (27 papers), Allergic Rhinitis and Sensitization (9 papers) and Histone Deacetylase Inhibitors Research (9 papers). Yuning Liao collaborates with scholars based in China and United States. Yuning Liao's co-authors include Hongbiao Huang, Xiaohong Xia, Jinbao Liu, Lili Jiang, Ningning Liu, Xuejun Wang, Chuyi Huang, Jianyu Cai, Zhenlong Shao and Yuan Liu and has published in prestigious journals such as Oncogene, Scientific Reports and Biochemical and Biophysical Research Communications.

In The Last Decade

Yuning Liao

56 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuning Liao China 25 1.1k 455 279 253 179 58 1.6k
Nina V. Chaika United States 22 1.1k 0.9× 661 1.5× 180 0.6× 662 2.6× 219 1.2× 32 1.8k
Stephan Singer Germany 28 1.2k 1.0× 458 1.0× 201 0.7× 468 1.8× 279 1.6× 76 2.1k
Sally Przybranowski United States 16 1.8k 1.5× 757 1.7× 297 1.1× 187 0.7× 119 0.7× 24 2.5k
Kathleen D. Whitney United States 16 775 0.7× 695 1.5× 135 0.5× 318 1.3× 146 0.8× 25 1.6k
Lisa M. Greene Ireland 21 592 0.5× 259 0.6× 247 0.9× 230 0.9× 95 0.5× 35 1.7k
Tingting Zhao China 25 759 0.7× 314 0.7× 157 0.6× 288 1.1× 92 0.5× 74 1.5k
Debdutta Bandyopadhyay United States 20 1.1k 1.0× 488 1.1× 105 0.4× 176 0.7× 154 0.9× 34 1.6k
Connie L. Erickson‐Miller United States 25 678 0.6× 237 0.5× 208 0.7× 414 1.6× 73 0.4× 53 2.4k
Michael Fraser Canada 24 1.4k 1.2× 562 1.2× 561 2.0× 479 1.9× 131 0.7× 47 2.3k
Birgit Bossenmaier Germany 19 807 0.7× 816 1.8× 180 0.6× 87 0.3× 68 0.4× 42 1.8k

Countries citing papers authored by Yuning Liao

Since Specialization
Citations

This map shows the geographic impact of Yuning Liao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuning Liao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuning Liao more than expected).

Fields of papers citing papers by Yuning Liao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuning Liao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuning Liao. The network helps show where Yuning Liao may publish in the future.

Co-authorship network of co-authors of Yuning Liao

This figure shows the co-authorship network connecting the top 25 collaborators of Yuning Liao. A scholar is included among the top collaborators of Yuning Liao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuning Liao. Yuning Liao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yao, Yu, et al.. (2024). METTL14-mediated m6A modification enhances USP22-ERα axis to drive breast cancer malignancy. Pharmacological Research. 210. 107509–107509. 4 indexed citations
2.
Huang, Hongbiao, Yuting Li, Qing Liu, et al.. (2024). The Ku70-SIX1-GPT2 axis regulates alpha-ketoglutarate metabolism to drive progression of prostate cancer. Oncogene. 44(2). 92–104. 2 indexed citations
3.
Shao, Zhenlong, Shutong Liu, Xiaohong Xia, et al.. (2024). SENP3 mediates deSUMOylation of SIX1 to promote prostate cancer proliferation and migration. Cellular & Molecular Biology Letters. 29(1). 146–146. 3 indexed citations
4.
Zhao, Ruijun, Yuting Li, Cuifu Yu, et al.. (2024). Ku70 targets BRD3-MYC/Cyclin D1 axis to drive hepatocellular carcinoma progression. Experimental Cell Research. 444(2). 114404–114404. 1 indexed citations
5.
Liao, Yuning, Yuan Liu, Cuifu Yu, et al.. (2023). HSP90β Impedes STUB1‐Induced Ubiquitination of YTHDF2 to Drive Sorafenib Resistance in Hepatocellular Carcinoma. Advanced Science. 10(27). e2302025–e2302025. 21 indexed citations
6.
Liu, Yuan, Cuifu Yu, Zhenlong Shao, et al.. (2022). SNS-023 sensitizes hepatocellular carcinoma to sorafenib by inducing degradation of cancer drivers SIX1 and RPS16. Acta Pharmacologica Sinica. 44(4). 853–864. 20 indexed citations
7.
Liao, Yuning, Yuan Liu, Xiaohong Xia, et al.. (2020). Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy. Theranostics. 10(8). 3366–3381. 58 indexed citations
8.
Liu, Yuan, Zhenlong Shao, Yuning Liao, et al.. (2020). Targeting SKP2/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation. European Journal of Pharmacology. 883. 173366–173366. 16 indexed citations
9.
Xia, Xiaohong, Jinchan He, Qiong Xu, et al.. (2020). USP10 deletion inhibits macrophage-derived foam cell formation and cellular-oxidized low density lipoprotein uptake by promoting the degradation of CD36. Aging. 12(22). 22892–22905. 15 indexed citations
10.
Zhong, Xiaomei, Yuning Liao, Xinru Chen, et al.. (2020). Abnormal Serum Bilirubin/Albumin Concentrations in Dementia Patients With Aβ Deposition and the Benefit of Intravenous Albumin Infusion for Alzheimer’s Disease Treatment. Frontiers in Neuroscience. 14. 859–859. 21 indexed citations
11.
Xia, Xiaohong, Chuyi Huang, Yuning Liao, et al.. (2019). Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide. Journal of Experimental & Clinical Cancer Research. 38(1). 220–220. 70 indexed citations
12.
Xia, Xiaohong, Yuning Liao, Chuyi Huang, et al.. (2019). Deubiquitination and stabilization of estrogen receptor α by ubiquitin-specific protease 7 promotes breast tumorigenesis. Cancer Letters. 465. 118–128. 76 indexed citations
13.
Liu, Ningning, Zhiqiang Guo, Xiaohong Xia, et al.. (2019). Auranofin lethality to prostate cancer includes inhibition of proteasomal deubiquitinases and disrupted androgen receptor signaling. European Journal of Pharmacology. 846. 1–11. 35 indexed citations
14.
Huang, Hongbiao, Ni Liu, Yuning Liao, et al.. (2017). Platinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibition. Journal of Experimental & Clinical Cancer Research. 36(1). 79–79. 20 indexed citations
15.
16.
Dong, Xiaoxian, Yuning Liao, Ningning Liu, et al.. (2016). Combined therapeutic effects of bortezomib and anacardic acid on multiple myeloma cells via activation of the endoplasmic reticulum stress response. Molecular Medicine Reports. 14(3). 2679–2684. 4 indexed citations
17.
Rachelefsky, Gary S., et al.. (2006). Inhaled Corticosteroids and the Risk of Oropharyngeal Adverse Events: Results from a Meta-Analysis. Journal of Allergy and Clinical Immunology. 117(2). S92–S92. 3 indexed citations
18.
Kaplan, Allen P., Sheldon L. Spector, Suzanne Meeves, et al.. (2005). Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Annals of Allergy Asthma & Immunology. 94(6). 662–669. 44 indexed citations
19.
20.
Kaliner, Michael, Martha V. White, Athena Economides, et al.. (2003). Relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal-and-flare suppression. Annals of Allergy Asthma & Immunology. 90(6). 629–634. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nina V. Chaika Breakdown of academic impact, for papers by Stephan Singer Breakdown of academic impact, for papers by Sally Przybranowski Breakdown of academic impact, for papers by Kathleen D. Whitney Breakdown of academic impact, for papers by Lisa M. Greene Breakdown of academic impact, for papers by Tingting Zhao Breakdown of academic impact, for papers by Debdutta Bandyopadhyay Breakdown of academic impact, for papers by Connie L. Erickson‐Miller Breakdown of academic impact, for papers by Michael Fraser Breakdown of academic impact, for papers by Birgit Bossenmaier
Rankless by CCL
2026